RIVIVE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rivive, and what generic alternatives are available?
Rivive is a drug marketed by Harm Reduction Therp and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-six countries.
The generic ingredient in RIVIVE is naloxone hydrochloride. There are twelve drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rivive
A generic version of RIVIVE was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
Summary for RIVIVE
International Patents: | 51 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in RIVIVE? | RIVIVE excipients list |
DailyMed Link: | RIVIVE at DailyMed |
Pharmacology for RIVIVE
Drug Class | Opioid Antagonist |
Mechanism of Action | Opioid Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for RIVIVE
US Patents and Regulatory Information for RIVIVE
RIVIVE is protected by two US patents.
Patents protecting RIVIVE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF INTRANASAL NALOXONE FOR THE TREATMENT OF OPIOID OVERDOSE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Harm Reduction Therp | RIVIVE | naloxone hydrochloride | SPRAY, METERED;NASAL | 217722-001 | Jul 28, 2023 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Harm Reduction Therp | RIVIVE | naloxone hydrochloride | SPRAY, METERED;NASAL | 217722-001 | Jul 28, 2023 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RIVIVE
See the table below for patents covering RIVIVE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Philippines | 12016501342 | INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | ⤷ Try a Trial |
Colombia | 6821959 | Formas de dosificación farmacéutica intranasales que comprenden naloxona | ⤷ Try a Trial |
Spain | 2661838 | ⤷ Try a Trial | |
Norway | 2706982 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RIVIVE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1685839 | 92292 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |